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Abstract
Introduction: Despite evidence-based guidelines for venous thromboembolism prevention, substantial variability is
found in practice. Many economic evaluations of new drugs for thromboembolism prevention do not occur
prospectively with efficacy studies and are sponsored by the manufacturers, raising the possibility of bias. We
performed a systematic review of economic analyses of venous thromboembolism prevention in hospitalized
patients to inform clinicians and policy makers about cost-effectiveness and the potential influence of sponsorship.
Methods: We searched MEDLINE, EMBASE, Cochrane Databases, ACP Journal Club, and Database of Abstracts of
Reviews of Effects, from 1946 to September 2011. We extracted data on study characteristics, quality, costs, and
efficacy.
Results: From 5,180 identified studies, 39 met eligibility and quality criteria. Each addressed pharmacologic
prevention: low-molecular-weight heparins versus placebo (five), unfractionated heparin (12), warfarin (eight), one
or another agents (five); fondaparinux versus enoxaparin (11); and rivaroxaban and dabigatran versus enoxaparin
(two). Low-molecular-weight heparins were most economically attractive among most medical and surgical
patients, whereas fondaparinux was favored for orthopedic patients. Fondaparinux was associated with increased
bleeding events. Newer agents rivaroxaban and dabigatran may offer additional value. Of all economic evaluations,
64% were supported by manufacturers of a “new” agent. The new agent had a favorable outcome in 38 (97.4%) of
39 evaluations [95% confidence interval [CI] (86.5 to 99.9)]. Among studies supported by a pharmaceutical
company, the sponsored medication was economically attractive in 24 (96.0%) of 25 [95% CI, 80.0 to 99.9)]. We
could not detect a consistent bias in outcome based on sponsorship; however, only a minority of studies were
unsponsored.
Conclusion: Low-molecular-weight heparins and fondaparinux are the most economically attractive drugs for
venous thromboembolism prevention in hospitalized patients. Approximately two thirds of evaluations were
supported by the manufacturer of the new agent; such drugs were likely to be reported as economically favorable.
Introduction
Venous thromboembolism occurs in up to 40% of hos-
pitalized medical and surgical patients in the absence of
prophylactic anticoagulation [1,2]. Even with prophy-
laxis, the risk of venous thromboembolism in critically
ill patients approaches 10% and has serious conse-
quences: untreated pulmonary embolism has a mortality
rate approaching 25% [3-5]. Among critically ill patients,
those developing venous thromboembolism have longer
intensive care unit and hospital stays, longer duration of
mechanical ventilation, and higher hospital mortality [6].
Consequently, venous thromboembolism not only is
associated with serious morbidity and mortality, but also
has major implications for healthcare resource
utilization.
Appropriate use of prophylaxis to prevent venous
thromboembolism in patients at risk has been identified
as one of the most important patient-safety interven-
tions for hospitals [7]. However, substantial variability is
found in the use of such prophylaxis in practice.
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Prevention is most commonly achieved with anticoagu-
lant drugs. Because important decisions about pharma-
cologic interventions are made with knowledge of their
economic consequences, formal economic analyses are
useful tools to guide clinicians and policy makers about
the value of drug interventions and their consequences
[8,9]. However, many evaluations of new drugs do not
occur prospectively with efficacy studies, and many are
sponsored by the manufacturers, raising the possibility
of bias.
We performed a systematic review of economic ana-
lyses of venous thromboembolism-prevention strategies
in acutely ill hospitalized patients. Our objectives were
to review and critically appraise the economic evalua-
tions of a broad spectrum of strategies in diverse patient
groups to help inform clinicians and policy makers
about the cost-effectiveness of various approaches to
venous thromboembolism prophylaxis.
Materials and methods
Date sources and searches
We searched MEDLINE, EMBASE, the Cochrane Data-
base of Systematic Reviews, ACP Journal Club, Database
of Abstracts of Reviews of Effects (DARE), and
Cochrane Controlled Trials Register from 1946 to Octo-
ber 21, 2011, by using a combination of the following
subject headings and text words: venous thrombosis, pul-
monary embolism, low-molecular-weight heparin,
LMWH, dalteparin, enoxaparin, nadroparin, tinzaparin,
heparin, unfractionated heparin, UFH, anticoagulants,
warfarin, aspirin, fondaparinux, rivaroxaban, dabiga-
tran, intermittent pneumatic compression devices, com-
pression stockings, vena cava filters, venous foot pump,
economics, health care cost, cost-effectiveness analysis,
cost-benefit analysis, and economic analysis (Additional
file 1). No limits regarding publication type were initially
applied. To identify additional potentially relevant stu-
dies, we checked the reference lists of identified sys-
tematic and narrative reviews and the personal files of
the authors and collaborators. We also sent the full list
of identified articles and inclusion criteria to venous
thromboembolism experts in the field to identify addi-
tional published or relevant unpublished studies.
Study selection
From 5,180 potentially relevant citations, 4,816 were
excluded based on title and abstract review (Figure 1).
The full text versions of 89 manuscripts were retrieved
for full evaluation. Two reviewers (ST, RF) indepen-
dently assessed each of the articles and applied the fol-
lowing eligibility criteria: (a) the economic evaluation
was based on data from randomized controlled trials or
meta-analyses of randomized controlled trials; (b). the
study described hospitalized patients; (c) the study
compared at least two different venous thromboembo-
lism prophylaxis strategies; (d) the study described drug-
acquisition costs, the costs of providing prophylaxis,
costs of complications (including venous thromboembo-
lism treatment and prophylaxis failures); and (e) the
study described the effect of prophylaxis with respect to
the number of venous thromboembolism events pre-
vented and diagnosed. We excluded evaluations based
on the following study designs: 1. cohort studies or
other observational studies; 2. studies on outpatient use
of venous thromboembolism prophylaxis; 3. studies on
the treatment of venous thromboembolism; 4. studies
examining the efficacy of short-term versus long-term
venous thromboembolism prophylaxis; 5. decision analy-
tic models based on data from nonrandomized trials; 6.
studies examining anticoagulants for conditions other
than venous thromboembolism, and seven letters, edi-
torials, or narrative reviews of economic issues in
venous thromboembolism prophylaxis. We also
excluded studies appraised as low to moderate quality,
as defined later.
Data extraction and quality assessment
We critically appraised each article by using established
criteria [9]. Our goal was to include only those studies
that adhered to a high methodologic quality. We
assigned an ordinal score of quality based on the criteria
set forth in the “User’s guide to the medical literature:
XIII. How to use an article on economic analysis of clin-
ical practice” [9]. With a semiquantitative scale incor-
porating these characteristics, we assigned 1 point for
each of the 12 categories. All studies were graded as
high (≥ 9 points), medium (5 to 8 points), or low (0 to 4
points) quality by two authors (ST, RF). Disagreements
about the inclusion of individual studies were resolved
by consensus between two authors (ST, RF). Of the 84
articles selected for full review, 50 were appraised as low
or moderate quality, and the remaining 39 studies were
selected for data abstraction.
We identified 10 economic evaluations of mechanical
prophylaxis, including intermittent pneumatic compres-
sion devices, compression stockings, or vena cava filters
[10-17]. None of these articles met our previously stated
eligibility criteria.
From each included study, we abstracted the follow-
ing: the patient group, venous thromboembolism pro-
phylaxis strategy, duration of prophylaxis, time frame of
the study, source of the outcome data, source of the
cost data, incremental costs and benefits of each strat-
egy, results of any sensitivity analyses, the country in
which the study was performed, and the declared source
of funding for the economic analysis. We attempted to
contact authors of studies for which no external support
was declared to ensure that this was the case.
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We abstracted the number of thrombotic events,
costs, and complication rates of the prophylaxis and of
the treatment of venous thromboembolism from each
article. We then recorded or calculated the incremental
cost-efficacy ratio for each venous thromboembolism
prophylaxis strategy. If we were unable to calculate the
incremental cost-efficacy ratio because of missing data,
we attempted to contact the authors to obtain this ratio
or original data. Costs were converted to 2009 US dol-









































5180 potentially relevant citations were identified and screened 
 1349 from Medline 
 2521 from Embase 
1310 from EBM Reviews (Cochrane Database of Systematic 
Reviews/Central Register of Controlled Trials/Methodology 
Register, ACP Journal Club, DARE, Health Technology 
Assessment, NHS Evaluation Database) 
39 articles included in final review 
4816 excluded based upon 
title and abstract 
364 articles retrieved for further evaluation 
275 articles excluded based upon abstract 
89 articles retrieved for evaluation of full text 
50 articles excluded based upon detailed evaluation 
- Not based upon RCTs 
- Did not describe costs/benefits 
- Did not describe in-patient prophylaxis 
Figure 1 Study eligibility diagram.
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in gross domestic product [18-20]. We standardized the
incremental effects we reported as “venous thromboem-
bolism events avoided,” “life-years or quality adjusted
life-years gained’ or ‘deaths avoided per 1000 patients’,
as is commonly performed in venous thromboembolism
literature. We chose in-hospital or near-term (< 90
days) events for the primary comparisons whenever pos-
sible, as the short and longer-term effects of inpatient
thromboprophylaxis are often greatest during this time
period.
Data synthesis and analysis
Heterogeneity of the interventions, perspectives, and
time-horizons precluded meta-analytic techniques to
combine incremental cost-efficacy ratios into a single
summary statistic. We summarized cost-effectiveness
ratios by graphic representation of point estimates on a
cost-efficacy plane. Categoric variables and proportions
were compared by using the c2 or Exact tests as
appropriate.
Results
Study comparisons, populations, and format
Among the 39 studies included in this review, the fol-
lowing comparisons were made: low-molecular-weight
heparins versus placebo (five) [20-24]; unfractionated
heparin versus low-molecular-weight heparins (12)
[21,23-33]; various low-molecular-weight heparins ver-
sus warfarin (eight) [34-41]; various low-molecular-
weight heparins compared with one another or other
agents (five) [31,42-45]; fondaparinux versus enoxaparin
(11) [46-56], rivaroxaban versus low-molecular-weight
heparins or dabigatran [57], and dabigatran versus low-
molecular-weight heparin [58] (Tables 1 and 2).
Twenty-six evaluations were performed in orthopedic
patients [25-27,34-43,46-58]; five in other surgical popu-
lations [28,30-32,44], and eight in medical patients
[20-24,29,33,45]. All 39 studies were either decision ana-
lytic models based on individual randomized controlled
trials [20-22,24,26,28,31-49,51-58] or meta-analysis
[23,27,29,30,51].
Study perspectives, time horizon, and funding
The studies were conducted from a North American or
European economic perspective: 18 of the studies were
conducted in the United States [26,29,31-41,45,48,
51-53,55], six in the United Kingdom [21,23,25,46,
57,58], four in Canada [23,28,34,51], and three in Italy
[27,30,44], two in Sweden [42,47], and one each in
Spain [43], Belgium [49], France [20], Norway [54],
Switzerland [56], and Germany [24]. Seven studies were
conducted from the perspective of the hospital
[24,41,42,44,45,49,53], four from a societal perspective
[20,28,30,32], nine from the perspective of another
specific payer [23,31,33,40,54-58], and the remaining 19
studies did not clearly specify which perspective was
used.
The prophylaxis time horizons considered were vari-
able: either for 5 days [33,51]; 7 days
[25,28,34,38,44,46-50,53-56]; 6 to 14 days [23]; 10 days
[31,32,37,40,41,52], 8 to 12 days [43]; 7 to 14 days [26];
6 to 14 days [57], 10 to 14 days [20,22-24,27,30,35,
36,39,42-46]; 30 days [29], 8 to 33 days [59], and
another for 8 weeks [45]. Twenty-five studies received
some sponsorship by pharmaceutical companies
[20,22-25,28,30,33-38,40,41,43,44,46,47,50,54-56,58].
Study quality
All 39 studies that were of high quality were included in
this systematic review (Table 2). Eighteen of these
showed complete cost data but did not present complete
effectiveness data [25-27,29,31,37-45,51,54-56]. The
remaining 17 studies had complete cost and effective-
ness data. Six of the studies obtained effectiveness data
from meta-analysis [23,25,27,31,50,57], whereas the
remainder obtained effectiveness data from one or more
randomized controlled trials. Six of these studies
obtained effectiveness data from a single trial
[20,22-24,33,41]. All studies, with the exception of one
[23], obtained cost data from multiple sources, including
actual and estimated healthcare system costs, rando-
mized controlled trials, literature reviews, and other
national government sources. All performed sensitivity
analyses of some description.
Table 1 Study characteristics
Study characteristics Number of
studies
Thromboprophylaxis compared
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Table 2 Study description and quality assessment
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Table 2 Study description and quality assessment (Continued)
Menzin,
1995
Enoxaparin 30 mg twice daily
versus warfarin (INR 2-3) versus








Hull, 1997 Warfarin versus tinzaparin 175










Enoxaparin 30 mg twice daily








Francis, 1999 Dalteparin 2,500 units, then 5,000








Yes; for costs Yes
Botteman,
2002
Enoxaparin 30 mg daily versus










Enoxaparin 30 mg twice daily for
7 days versus UFH 5,000 units 3









Levin, 2001 Desirudin 15 mg twice daily
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Dermatan sulfate 300 mg daily
versus UFH 5,000 units 3 times







Yes - data from
hospital costs
Yes Yes
Wade, 2001 Tinzaparin 3,500 units versus
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Wade, 2003 Fondaparinux 2.5 mg daily versus
enoxaparin 40 mg daily versus 30








Szucs, 2003 Fondaparinux 2.5 mg daily versus
enoxaparin 40 mg daily for 7 days
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Table 2 Study description and quality assessment (Continued)
Sullivan,
2004
Fondaparinux 2.5 mg daily versus
enoxaparin 40 mg daily for 7 days
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Spruill, 2004 Fondaparinux 2.5 mg daily versus
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Wade, 2004 Fondaparinux 2.5 mg daily versus










Fondaparinux 2.5 mg daily versus
enoxaparin 40 mg daily for 7 days











THR Dabigatran 220 mg daily
versus enoxaparin 40 mg daily for
28-35 days TKR Dabigatran 220
mg daily for versus enoxaparin 40











THR Dabigatran 220 mg daily for
35 days versus rivaroxaban 10 mg
daily for 35 days versus
enoxaparin 40 mg daily for 14
days TKR Dabigatran 220 mg daily
for 14 days versus rivaroxaban 10
mg daily for 10 days versus













Yes N/R No Yes Yes Yes
Lloyd, 2001 Yes N/R No Yes Yes Yes
Lamy, 2002 Yes N/R No Yes Yes Yes
Offord, 2003 Yes N/R No Yes Yes Yes
Schadlich,
2006
Incompletely N/R No Yes Yes Yes
Drummond,
1994
Incompletely N/R No Yes Yes Likely
Hawkins,
1997
Yes N/R No Yes Yes Yes
Marchetti,
1999
Incompletely N/R No Yes Yes Yes
Etchells,
1999
Yes N/R No Yes Yes Yes
McGarry,
2004
Incompletely N/R No Yes Yes Yes
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Cost and effect estimates
Low Molecular Weight Heparins versus Placebo
Among the five studies comparing low-molecular-weight
heparins with placebo in medical patients, enoxaparin
was the most economically attractive strategy in all five
studies and dominant in two [20,22], with incremental
cost-efficacy ratios ranging from $83 to $1,711 per
venous thromboembolism event avoided in three others
Table 2 Study description and quality assessment (Continued)
Heerey,
2005
Incompletely N/R No Yes Yes Likely
Deitelzweig,
2008
Yes N/R No Yes Yes Likely
Wade, 2008 Yes Yes Yes Yes Yes Yes
O’Brien,
1994
Yes N/R No Yes Yes Yes
Menzin,
1995
Yes N/R No Yes Yes Yes
Hull, 1997 Yes N/R No Yes Yes Yes
Hawkins,
1998
Yes N/R No Yes Yes Yes
Francis, 1999 Yes Yes Yes Likely Yes Yes
Botteman,
2002
Incompletely N/R No Yes Perhaps Yes
Nerurkar,
2002
Incompletely N/R No Yes Perhaps Yes
Levin, 2001 Incompletely N/R No Yes Yes Likely
Caprini,
2002
Yes Yes No Yes Yes Likely































Yes N/R No Yes Yes Yes
Wade, 2001 Incompletely N/R No Yes Yes Yes
Gordois,
2003
Yes N/R No Yes Yes Yes
Wade, 2003 Yes N/R No Yes Yes Yes
Annemans,
2004
Yes N/R No Yes Yes Yes
Attanasio,
2001
Yes N/R No Yes Yes Yes
Szucs, 2003 Yes Yes No Yes Yes Yes
Sullivan,
2004
Yes Yes No Yes Yes Yes
Dranitsaris,
2004
Yes N/R No Yes Yes Yes
Spruill, 2004 Yes N/R No Yes Yes Yes
Spruill, 2004 Yes N/R No Yes Yes Yes
Wade, 2004 Yes N/R No Yes Yes Yes
Bjorvatn,
2005
Yes Yes No Yes Yes Yes
Wolowacz
2009
Yes Yes No Yes Yes Yes
McCullagh
2009
Yes Yes No Yes Yes Yes
CIHI, Canadian Institute for Health Information; DRG, diagnosis-related group; HFS, hip fracture surgery; NICE, National Centre for Clinical Excellence
N/R, not reported; OHIP, Ontario Health Insurance Plan; RCT, randomized controlled trial; THR, total hip replacement; TKR, total knee replacement; UFH,
unfractionated heparin.
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[21,23,24]; cost per life-year or quality-adjusted life-year
gained were not investigated (Table 3). Sensitivity analy-
sis did not alter these findings. Four of the five studies
were sponsored by the manufacturer of enoxaparin
[20-22,24].
Unfractionated Heparin versus Low Molecular Weight
Heparins
Among the 12 studies comparing low-molecular-weight
heparins with unfractionated heparin among medical
and surgical patients, 11 found that low-molecular-
weight heparins were more effective (Table 3 and Figure
2). Eight of the 12 studies comparing low-molecular-
weight heparins with unfractionated heparin found low-
molecular-weight heparins to be the dominant strategy
[21,23-25,27,29,30,32,33]. Two studies reported an incre-
mental cost-efficacy ratio of $1,180 and $1,445 per
venous thromboembolism event avoided when using
enoxaparin [26,29], and two studies found incremental
cost-effectiveness ratios of $10,360 per death avoided
and $20,337 per quality-adjusted life-year gained with
low-molecular-weight heparins. A single study of venous
thromboembolism prevention among patients under-
going colorectal cancer surgery found no difference in
efficacy, yet costs of low-molecular-weight heparins
were greater [28]. Three studies reported increased
bleeding risk with low-molecular-weight heparins, and
three studies reported lower risk. Sensitivity analyses did
not change these results. Of these 12 studies, eight
received financial support from the manufacturer of the
low-molecular-weight heparins [23-26,28-30,33].
Warfarin versus Low-Molecular-Weight Heparins
Low-molecular-weight heparins were reported to be
economically more attractive than warfarin in all eight
studies among surgical patients, with incremental cost-
efficacy ratios of $874 to $26,711 per venous throm-
boembolism event avoided in five of the comparisons
[34,35,37,38,40], the dominant strategy in three compar-
isons [36,39,41]. Long-term outcomes varied widely,
with $16,200 to $334,055 per death avoided, $32,158 per
life-year and $4,340 per quality-adjusted life-year gained
(Table 3 and Figure 3) [34,38]. Sensitivity analyses did
not change the results in individual studies. Of these
eight studies, seven received pharmaceutical sponsorship
[34-38,40,41].
Low-Molecular-Weight Heparins versus One another, and
Other Comparisons
Within the studies comparing low-molecular-weight
heparins with one another and with other anticoagulants
among surgical patients, bemiparin and dermatan sulfate
were the dominant prophylaxis over enoxaparin [43,44].
Desirudin had an incremental cost-effectiveness ratio of
$3,794 per life-year gained, whereas enoxaparin was
favored over tinzaparin but was more expensive (Table
3) [45]. Dalteparin, 5,000 units once daily, was more
efficacious than dalteparin, 2,500 units, with an incre-
mental cost-effectiveness ratio of $24,357 per quality-
adjusted life-year gained [30].
Fondaparinux versus Low Molecular Weight Heparins
Among the 11 studies comparing fondaparinux with
enoxaparin, all were conducted in orthopedic surgery
patients, and all concluded that fondaparinux was eco-
nomically attractive. In six, fondaparinux was dominant
[47,51-53,55,56], and in one, enoxaparin [48] (Table 3
and Figure 4). In four studies, incremental cost-effective-
ness ratios of fondaparinux over enoxaparin were $158
to $1,077 per venous thromboembolism event avoided,
$104 to $6,782 per death avoided, and $32,144 per qual-
ity-adjusted life-year gained [46,49,53,54]. In eight of 11
studies, fondaparinux was associated with increased
bleeding risk. Sensitivity analyses of the various costs
did not alter the findings. The manufacturer of fonda-
parinux provided sponsorship for six of the 11 studies.
Dabigatran and Rivaroxaban versus Low Molecular Weight
Heparins
Among orthopedic patients, dabigatran, in comparison
with enoxaparin, was dominant, with cost savings of
$103,050 and $8,162 and six and seven quality-adjusted
life-years gained per 1,000 patients with a total hip repla-
cement and total knee replacement, respectively [58].
Comparing rivaroxaban, dabigatran, and enoxaparin
among orthopedic surgery patients, rivaroxaban was domi-
nant, with cost savings of $24,104 and $213,452 and 7 life-
years gained per 1,000 patients with a total hip replace-
ment and total knee replacement, respectively [57].
Sponsorship and Economic Comparisons
When comparing different populations and the different
modes of venous thromboembolism prophylaxis, we
observed several interesting trends. All studies compar-
ing fondaparinux, rivaroxaban, or dabigatran with enox-
aparin were performed in orthopedic patients, and the
remainder of the studies in this patient population
examined various low-molecular-weight heparins or
warfarin. Sixteen of the 25 studies among orthopedic
patients were sponsored in some manner by the phar-
maceutical industry: six studies favored fondaparinux
[46,47,50,54-56]; one, rivaroxaban [57]; one, dabigatran
[58]; and the remainder favored low-molecular-weight
heparins [25,34-38,40,41,43]. In comparison, five of the
eight studies conducted in medical patients compared
enoxaparin with placebo [20-24]; two compared unfrac-
tionated heparin with enoxaparin [29,33]; and the final
one compared enoxaparin with tinzaparin [45]. Five of
these eight studies were sponsored by pharmaceutical
companies, and all studies favored enoxaparin
[20,22-24]. Of the five studies in other surgical popula-
tions, three were sponsored by the pharmaceutical
industry, and these studies favored unfractionated
heparin [28], nadroparin [30], and dermatan sulfate [44].
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Table 3 Incremental costs, effects, and cost-efficacy ratios for the different modes of venous thromboembolism
prophylaxis


























Enoxaparin dominant Not reported Enoxaparin
Lloyd, 2001 Medical $20,680 per
1,000 patients
with enoxaparin
20 VTE events avoided
per 1,000 patients with
enoxaparin
$1, 034 per VTE
avoided with
enoxaparin
Six more major bleeding
events per 1,000 patients with
enoxaparin
Enoxaparin





2.3% fewer VTE events
with enoxaparin
$83 per VTE avoided
with enoxaparin
Not reported Enoxaparin








Enoxaparin dominant Not reported Enoxaparin
*Schaldich, 2006 Medical $44,665 per
1,000 patients
with enoxaparin
26 VTE events avoided
per 1,000 patients with
enoxaparin




























per 1,000 patients with
enoxaparin






47 DVT events avoided
per 1,000 patients with
enoxaparin













70 life-years gained per,
1000 patients with
enoxaparin








0 VTE events avoided
with enoxaparin









21 VTE events avoided
per 1,000 patients with
enoxaparin



























2.7% fewer bleeding events,









N/R Enoxaparin dominant 7.7 fewer major bleeding
episodes with enoxaparin
Enoxaparin
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Enoxaparin dominant Five major bleeding events,
four episodes of HIT avoided
















Enoxaparin dominant 21 additional major bleeding









50 VTE events avoided
per 1,000 patients with
enoxaparin











































































60 VTE events avoided
per 1,000 patients with
LMWH
LMWH dominant 2.2% increase in major







145 VTE events avoided
per 1,000 patients with
LMWH
$874 per VTE event
avoided with LMWH
0.3% increased risk of major
bleeding event with LMWH
LMWH





112 VTE events avoided
per 1,000 patients with
LMWH









77 DVTs avoided per
1,000 patients, 40















per 1,000 patients with
LMWH
LMWH dominant Not reported LMWH
*Caprini, 2002 THR $110,235 per
1,000 patients
with LMWH
5.8 VTE events avoided
per 1,000 patients with
LMWH
$19,006 per VTE event
avoided with LMWH
Not reported LMWH
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42 VTE events avoided
per 1,000 patients with
bemiparin













70 DVTs avoided and
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Three VTE events per
1,000 patients with
enoxaparin




more bleeding episodes per
1,000 patients with enoxaparin












17.7 VTE events per
1,000 patients with
fondaparinux






















10 more major bleeding events
per 1,000 patients with
fondaparinux
Fondaparinux







36 VTE events avoided




10 more major bleeds and
three more minor bleeding
events per 1,000 patients with
fondaparinux
Fondaparinux
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Of the economic evaluations included in this review, 25
(64%) received funding by manufacturers of one of the
comparators. The “new” agent within the comparison was
deemed to have a favorable (dominant or attractive incre-
mental cost-effectiveness ratio) outcome in 38 (97.4%) of
the 39 economic evaluations (95% CI, 86.5% to 99.9%).
Among the 25 studies funded by a pharmaceutical com-
pany, the sponsored medication was reported to be eco-
nomically attractive in 24 (96.0%) (95% CI, 80.0% to 99.9%).
Discussion
In this systematic review of economic analyses of venous
thromboembolism-prevention strategies in hospitalized
patients, we found that all of the high-quality studies
focused on pharmacologic prophylaxis. Low-molecular-
weight heparins were the most commonly studied “new”
class of medication and were generally reported to be
the dominant or economically attractive strategy in
comparison with placebo, unfractionated heparin, or
warfarin, among medical and surgical patients. However,
among orthopedic patients, fondaparinux was favored
over low-molecular-weight heparins. The two newest
agents, dabigatran and rivaroxaban, are favored in the
two most recent orthopedic surgery evaluations included
in this review. Among the various strategies compared,
the new agent had a favorable cost-efficacy ratio in 97%
Table 3 Incremental costs, effects, and cost-efficacy ratios for the different modes of venous thromboembolism pro-
phylaxis (Continued)







20 VTE events avoided




19 more major bleeding events
per 1,000 patients with
fondaparinux
Fondaparinux




34 VTE events avoided
per 1,000 patients with
fondaparinux





bleeding costs for fondaparinux
Fondaparinux







3.7 VTE events avoided















8.1 VTE events avoided














7.2 VTE events avoided
per 1,000 patients with
fondaparinux




Two more bleeding events per
1,000 patients treated with
fondaparinux
Fondaparinux
Dabigatran versus rivaroxaban and low-molecular-weight heparins







QALYs gained per 1,000
patients treated with
dabigatran
Dabigatran dominant Five additional major bleeding
events, two episodes HIT













Dabigatran dominant Six additional major bleeding
events, two episodes HIT
avoided per 1,000 patients
treated with dabigatran




















HFS, hip-fracture surgery; ICER, incremental cost-efficacy ratio; LMWH, low-molecular-weight heparin; THR, total hip replacement; UFH, unfractionated heparin;
USD, United States dollars; VTE, venous thromboembolism. *Industry-sponsored study.
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of the studies, and most of these studies were sponsored
by the manufacturers of the new agent.
Few systematic reviews of economic analyses compar-
ing different modes of venous-thromboembolism pro-
phylaxis in hospitalized patients have been conducted.
In 1994, one such review of cost-efficacy analyses of
low-molecular-weight heparins, unfractionated heparin,
and warfarin in the prevention and treatment of venous
thromboembolism in surgical patients, concluded that
low-molecular-weight heparin was more efficacious and
cost-effective after total hip arthroplasty [34]. Most





& more efficacious 
LMWH cheaper 
& more efficacious 
Figure 2 Comparison of the incremental effects and costs of low-molecular-weight heparin versus unfractionated heparin for venous
thromboembolism prophylaxis.
Figure 3 Comparison of the incremental effects and costs of low-molecular-weight heparin versus warfarin for venous
thromboembolism prophylaxis.
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with unfractionated heparin in hospitalized patients
found low-molecular-weight heparin to be cost saving
compared with unfractionated heparin and that low-
molecular-weight heparin was associated with a lower
venous thromboembolism readmission rate at 30 and 90
days [59]. Our review includes 37 subsequently pub-
lished analyses, focusing on both medical and surgical
patient populations, and comparing newer pharmacolo-
gic agents for venous thromboembolism prophylaxis,
such as fondaparinux, dabigatran, and rivaroxaban.
In this review, low-molecular-weight heparins
appeared to offer superior prophylaxis efficacy compared
with warfarin, unfractionated heparin, and placebo for
orthopedic, general surgical, and medical patients. Fon-
daparinux was found to be economically more attractive
for venous thromboembolism prevention compared with
heparins because of greater efficacy in surgical and
orthopedic patients, but may also be associated with
increased bleeding. Among 11 economic analyses com-
paring enoxaparin with fondaparinux, all found that fon-
daparinux was economically attractive. More than half
of these studies were either directly sponsored by the
manufacturers of fondaparinux, or were based on origi-
nal randomized controlled trials funded by the
manufacturer.
Historically, many economic evaluations of new drugs
have been sponsored by the drug manufacturer. How-
ever, this introduces the potential for bias in model con-
struction and interpretation of the results. In a
retrospective analysis of 107 trials in five leading medi-
cal journals with regard to outcome and sources of
funding, studies sponsored by pharmaceutical companies
were much less likely to favor traditional therapy over
new drug treatment [60,61]. It is not surprising that
new agents are incrementally efficacious; this is the nat-
ure of progress in medicine. However, new agents, typi-
cally still under patent protection, are virtually always
substantially more expensive than comparator drugs. In
our systematic review, 25 of the 39 studies were funded
by pharmaceutical companies, and, with the exception
of a single study [28], each of these found the sponsored
drug more economically attractive than the comparator
drug. Such consistency in incremental cost-effectiveness
among more-expensive drugs is striking. Importantly,
we could not detect a consistent bias in outcome
between sponsored and nonsponsored evaluations; how-
ever, only a minority of evaluations did not receive
sponsorship.
Strengths of our review include adherence to rigorous
systematic review methods, which consisted of a com-
prehensive search strategy, broad eligibility criteria, and
study selection by two independent adjudicators using a
priori criteria to minimize selection bias. Economic ana-
lyses are susceptible to investigator bias, often due to
retrospective decision-model generation and retrospec-
tive acquisition of cost-and-effect data. To reduce this
risk, we included only economic evaluations that incor-
porated outcome data from prospective randomized
controlled trials. We conducted data abstraction and cri-
tical appraisal in duplicate, by using established criteria
for assessing economic evaluations. We also addressed
the relation of recency to market and for-profit
Figure 4 Comparison of the incremental effects and costs of low-molecular-weight heparin versus fondaparinux for venous
thromboembolism prophylaxis.
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sponsorship in influencing the reporting of economic
evaluations. This review also has limitations. Many of
the analyses within studies that we included come from
a limited number of trials and cost-comparison models.
For example, five studies used outcome data from the
MEDENOX trial [20,22-24,33]. If most of the data are
derived from a limited number of efficacy trials and cost
models, similar results are likely to be found across eco-
nomic evaluations. Although the studies included in this
review received high ratings of internal validity, studies
varied widely with respect to patient population, time-
horizon of therapy, and payer perspective, making gen-
eralizability to other health care difficult. In addition,
many evaluations rely on radiologic as opposed to clini-
cal venous thromboembolism detection, which may
overestimate the real-life clinical consequences of
venous thromboembolism. Side effects of thrombopro-
phylaxis may be underestimated, as randomized con-
trolled trials often exclude patients at higher risk of
bleeding. Furthermore, trials are generally underpowered
to detect differences in rare drug-specific complications
such as heparin-induced thrombocytopenia. This may
lead to an overestimation of cost-efficacy, as reported in
the economic evaluations in this review. Finally, our
review included a predominance of orthopedic, general
surgery, and medical patients, and thus, our findings
may not generalizable to other patient populations.
Among economic analyses in this review, incremental
cost-effectiveness ratios were commonly expressed in
costs per venous thromboembolism events avoided, and
they ranged from $500 to $8,000 per venous thromboem-
bolism event avoided. These ranges are difficult to inter-
pret, as no firmly established willingness-to-pay
benchmarks exist for venous thromboembolism preven-
tion. Costs per life-year or quality-adjusted life-year
gained were less commonly reported, making economic
comparisons of venous thromboembolism-prevention
strategies and other interventions in healthcare similarly
challenging. Comparing and combining ICERs performed
with country-specific costs is challenging, as patient, dis-
ease, provider, and health-care system factors may influ-
ence transferability. We have not adjusted costs based on
country-specific purchasing power parity but have
adjusted based on changes in gross domestic product
over time, and country-specific exchange rates [62].
An informative economic analysis should include both
benefits and harms of interventions and the full asso-
ciated costs over a relevant time horizon. Full costs of
venous thromboembolism prophylaxis were not included
in some studies. The common complications of venous
thromboembolism prophylaxis include prophylaxis fail-
ure, leading to thrombotic events, bleeding, and
heparin-induced thrombocytopenia [1]. All 39 studies
evaluated in this systematic review accounted for
breakthrough thrombotic events; however, only half
included bleeding complications (Table 3), and none
fully accounted for heparin-induced thrombocytopenia.
The omission of these potentially serious complications
may considerably affect the cost-comparison data of the
individual studies. Most studies ascertained costs retro-
spectively and from the literature. This is often less
complete or less accurate compared with prospective
determination alongside a randomized controlled trial.
Finally, none of the studies included in this review was
prospectively designed before results of the randomized
controlled trials were published; accordingly, they may
be at risk for subjective decision-tree construction and
interpretation.
Few studies have evaluated the cost-effectiveness of
mechanical venous thromboembolism-prevention strate-
gies, and none of the existing studies met our eligibility
criteria. The UK National Institute for Health and Clini-
cal Excellence have recommended considering graduated
compression stockings in most patients, although eco-
nomic evaluations of mechanical venous thromboembo-
lism prophylaxis have generally been of low quality [63].
The paucity of rigorous evidence about the cost effec-
tiveness of mechanical prophylaxis is striking. However,
this may be explained by the fact that manufacturers of
mechanical devices are often not required to furnish
either effectiveness or cost data to regulatory bodies
before their introduction and marketing.
Conclusion
In this systematic review of economic analyses of venous
thromboembolism-prevention strategies in hospitalized
patients, we found that low-molecular-weight heparins
appear to be the most economically attractive strategy for
venous thromboembolism prevention among the major-
ity of medical and surgical patients, whereas fondapari-
nux is more economically attractive for orthopedic
patients. The studies, however, may be at risk of overesti-
mating efficacy and underestimating side effects such as
bleeding. Approximately two thirds of all evaluations
were directly funded by the manufacturer of the new
drug, and such drugs were more likely to be found eco-
nomically attractive in comparison to other strategies.
Limited opportunity for peer-reviewed and independent
funding for economic evaluations unfortunately leads to
reliance on industry sponsorship in this field. In the
future, we recommend that high-quality, prospective,
cost-effectiveness analysis be planned alongside the inter-
vention trials and that these be designed, conducted, ana-
lyzed, and reported independent of industry sponsors.
Key messages
• Low-molecular-weight heparins appear to be the
most economically attractive strategy for venous
Thirugnanam et al. Critical Care 2012, 16:R43
http://ccforum.com/content/16/2/R43
Page 16 of 19
thromboembolism prevention among the majority of
medical and surgical patients, whereas fondaparinux
is more economically attractive for orthopedic
patients.
• However, approximately two thirds of all evalua-
tions were directly funded by the manufacturer of
the new drug.
• Such drugs were more likely to be found econom-
ically attractive in comparison to other strategies.
• Limited opportunity for peer-reviewed and inde-
pendent funding for economic evaluations may lead
to reliance on industry sponsorship and bias in this
field.
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